At BioStem Technologies, healthy, safe and effective recovery of patients is our main focus. All of our products are produced accordance with the FDA regulations for Good Tissue Practices.
Human perinatal tissue derived allografts have been used in allogeneic transplants since the beginning of the last century. Their anti-inflammatory, anti-microbial, and immune privileged properties make them ideal candidates for novel applications across a wide range of medical disciplines. With continued clinical success, perinatal tissues are increasingly adopted as a preferred treatment platform.
The products offered by BioStem Technologies™ include RHEO™, OROPRO™, VENDAJE™, and VENDAJE™ OPTIC are perinatal tissue-derived allografts. They are designated as Human Cell, Tissue, and Cellular and Tissue-Based Products (HCT/P) by the U.S. Food and Drug Administration (FDA), are minimally manipulated, and are produced in accordance with the FDA regulations for Good Tissue Practices (21 CFR 1270, 1271).
